- Home
- GTLS vs CORT Comparison
GTLS vs CORT Comparison
Compare GTLS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTLS
- CORT
- Stock Information
- Founded
- GTLS 1859
- CORT 1998
- Country
- GTLS United States
- CORT United States
- Employees
- GTLS N/A
- CORT N/A
- Industry
- GTLS Metal Fabrications
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- GTLS Industrials
- CORT Health Care
- Exchange
- GTLS Nasdaq
- CORT Nasdaq
- Market Cap
- GTLS 7.4B
- CORT 7.6B
- IPO Year
- GTLS 1992
- CORT N/A
- Fundamental
- Price
- GTLS $199.46
- CORT $69.36
- Analyst Decision
- GTLS Buy
- CORT Strong Buy
- Analyst Count
- GTLS 14
- CORT 4
- Target Price
- GTLS $200.50
- CORT $138.25
- AVG Volume (30 Days)
- GTLS 2.3M
- CORT 628.8K
- Earning Date
- GTLS 10-31-2025
- CORT 10-29-2025
- Dividend Yield
- GTLS N/A
- CORT N/A
- EPS Growth
- GTLS 176.90
- CORT N/A
- EPS
- GTLS 5.39
- CORT 1.11
- Revenue
- GTLS $4,253,100,000.00
- CORT $716,080,000.00
- Revenue This Year
- GTLS $12.49
- CORT $30.62
- Revenue Next Year
- GTLS $9.94
- CORT $37.68
- P/E Ratio
- GTLS $37.00
- CORT $62.24
- Revenue Growth
- GTLS 8.95
- CORT 25.71
- 52 Week Low
- GTLS $101.60
- CORT $33.66
- 52 Week High
- GTLS $220.03
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- GTLS 71.06
- CORT 44.94
- Support Level
- GTLS $197.30
- CORT $68.82
- Resistance Level
- GTLS $199.38
- CORT $72.52
- Average True Range (ATR)
- GTLS 0.81
- CORT 1.62
- MACD
- GTLS -1.04
- CORT -0.09
- Stochastic Oscillator
- GTLS 99.60
- CORT 33.51
About GTLS Chart Industries Inc.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.